TYK Medicines, Inc. (浙江同源康醫藥股份有限公司, stock code: 2410) obtained listing approval from The Stock Exchange of Hong Kong Limited on February 11, 2026, for the conversion of 4.61 million unlisted shares into H shares. These shares represent about 1.21% of the company’s total issued share capital.

Upon completion of the conversion, TYK Medicines will have 380.07 million H shares, compared to the previous structure of 375.46 million H shares and 4.61 million unlisted shares. This move enables full circulation of the company’s H shares, and relevant conversion and trading procedures will be finalized in accordance with regulatory requirements. Shareholders and investors are advised to monitor official updates for further details.